Top Clinical Trial Companies (CROs) Globally based on Q2 2025 Revenue
The global clinical trial services market was valued at USD 76.70 billion in 2024 and is projected to reach USD 132.05 billion by 2033, showing a CAGR of 6.3% from 2025-2033. The US leads in clinical trial activity, followed by China and India. Key players like Thermo Fisher Scientific (PPD Division), IQVIA, ICON plc, WuXi AppTec, Pharmaron, Charles River Laboratories, Fortrea, and Medpace demonstrated significant revenue in Q2 2025, buoyed by strong backlogs and increasing investor confidence in the sector.
What Are Wall Street Analysts' Target Price for Charles River Laboratories Stock?
Charles River Laboratories International, Inc. (CRL) provides drug discovery and development services. Despite underperforming the broader market and the Health Care Select Sector SPDR Fund (XLV) over the past year, CRL recently reported strong Q4 results, beating Wall Street expectations for both EPS and revenue. Analysts have a "Moderate Buy" consensus rating for CRL stock, with a mean price target suggesting a significant premium from current levels.
Charles River Faces Soft Near-Term Outlook; Focus Remains on Cost Savings and Efficiency Initiatives
Charles River Laboratories International (CRL) is facing a soft near-term outlook with booking improvements but a weak 2026 revenue forecast. The company, which provides research models and drug development services, will focus on cost savings and efficiency initiatives to navigate these challenges. This strategy aims to improve its financial performance despite the current headwinds.
Charles River Laboratories NYSE CRL Quarterly Profit Streak Tests Bearish Profitability Narrative
Charles River Laboratories International (CRL) has reported three consecutive quarters of profit in FY 2025, contrasting with a trailing 12-month net loss of US$83.5 million. While analysts expect future growth, the company's valuation remains discounted against models assuming healthy margins, reflecting skepticism due to its past record of widening losses despite high revenue. The article highlights both bullish and bearish perspectives on CRL's path to sustained profitability.
Charles River Laboratories NYSE CRL Quarterly Profit Streak Tests Bearish Profitability Narrative
Charles River Laboratories International (CRL) recently reported its FY 2025 third-quarter numbers, showing a revenue of US$1,004.9 million and EPS of US$1.11, moving away from a previous net loss. The company has posted three consecutive quarters of positive net income in FY 2025, contrasting with a trailing 12-month net loss of US$83.5 million. While analysts expect continued growth and a return to profitability over the next three years, skeptics note that the trailing 12-month EPS remains a loss and historical losses have widened, suggesting the recovery is still in its early stages.
Truist Securities Cuts IQVIA Price Target to $245 From $290, Maintains Buy Rating
Truist Securities has lowered its price target for IQVIA Holdings Inc. (IQV) to $245 from $290, while reiterating a Buy rating on the stock. This adjustment comes despite competitor Charles River forecasting an upbeat 2026 profit due to improved demand for drug development services. Other analysts, including TD Cowen, UBS, Leerink Partners, and Evercore ISI, have also recently adjusted their price targets for IQVIA.
Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2025 Earnings Call Transcript
Charles River Laboratories International (NYSE:CRL) reported its Q4 and full-year 2025 earnings, with Q4 EPS missing expectations at -$5.62 against an anticipated $2.33. CEO James C. Foster announced his retirement in May, with Birgit H. Gershick appointed as the new CEO. The company provided 2026 guidance, expecting organic revenue to range from down 1% to flat, driven by improved DSA demand, strategic acquisitions, and cost-saving initiatives, despite some headwinds in RMS and Manufacturing.
Charles River Lab Loss Widens In Q4; Guides FY26
Charles River Laboratories International, Inc. (CRL) reported a wider net loss in the fourth quarter of the previous year and provided guidance for the full year 2026. The company's net loss attributable to the company increased to $276.29 million, with adjusted net income declining to $118.84 million. For 2026, the company expects revenue to range from flat to up 1.5% and adjusted earnings per share between $10.70 and $11.20, expressing optimism about improving demand.
Glenn Coleman and Kerry Dailey to join Charles River Labs leadership
Charles River Laboratories International, Inc. (NYSE:CRL) has announced the appointment of Glenn G. Coleman as Corporate Executive Vice President and Chief Financial Officer, and Kerry Dailey as Corporate Senior Vice President and Chief Legal Officer. These appointments are part of an organizational transformation aimed at strengthening the leadership team to meet evolving industry needs. The company's stock is currently trading at $158.53, with InvestingPro analysis suggesting it is undervalued, and analysts predict profitability for fiscal 2025 despite a loss over the last twelve months.
JPMorgan Cuts Charles River Laboratories International Price Target to $165 From $190, Maintains Neutral Rating
JPMorgan has reduced its price target for Charles River Laboratories International (NYSE: CRL) to $165 from $190, while maintaining a Neutral rating on the stock. This adjustment reflects an updated outlook from the investment bank. The article also notes recent adjustments to price targets and ratings from other firms like Jefferies, Barclays, and Baird for Charles River Laboratories International.
C-suite changes continue at Charles River with new CFO, legal chief
Charles River Laboratories is undergoing significant leadership changes, appointing a new CFO and legal chief amidst declining revenue and pressure from an activist shareholder. Longtime CEO Jim Foster is also set to retire after three decades with the company. These changes come as the company seeks to address its financial performance and shareholder concerns.
New Charles River Leaders May Shape Valuation, Debt And Governance Outlook
Charles River Laboratories International (NYSE:CRL) has appointed Glenn G. Coleman as Chief Financial Officer and Kerry Dailey as Chief Legal Officer, aiming to strengthen financial oversight, legal governance, and corporate compliance. These leadership changes are significant for investors as they may influence capital allocation, risk management, regulatory affairs, and the company's approach to its high debt levels. The article suggests investors monitor their impact on future financial performance and governance.
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance
Charles River Laboratories reported its financial results for the fourth quarter and full-year 2025, showing a slight decrease in revenue for both periods, reaching $994.2 million and $4.02 billion respectively. The company experienced GAAP net losses but presented positive non-GAAP earnings per share. Looking ahead, Charles River Laboratories provided 2026 guidance, anticipating organic revenue growth in the second half of the year and an increase in non-GAAP earnings per share by approximately 4% to 9%.
New Charles River Leaders May Shape Valuation, Debt And Governance Outlook
Charles River Laboratories International (NYSE:CRL) has appointed Glenn G. Coleman as Chief Financial Officer and Kerry Dailey as Chief Legal Officer. These new leadership roles are expected to influence the company's financial oversight, capital allocation, debt management, and regulatory compliance, particularly given the company's current high debt level. Investors will be watching how these executives shape decision-making and report on these matters in future communications.
Charles River Laboratories Announces Executive Appointments
Charles River Laboratories International, Inc. (NYSE: CRL) has announced two key executive appointments: Glenn G. Coleman as Chief Financial Officer and Kerry Dailey in the newly created role of Chief Legal Officer. These appointments are part of strengthening the company's leadership team to meet evolving client needs and industry demands, focusing on transformation, growth, efficiency, and operational excellence. Both Coleman and Dailey bring extensive experience in their respective fields within the healthcare and life sciences sectors.
Charles River Laboratories International (NYSE:CRL) Issues Quarterly Earnings Results
Charles River Laboratories International (NYSE:CRL) reported its quarterly earnings, beating analyst estimates with $2.39 EPS on $994.2 million revenue, despite a year-over-year revenue decrease of 0.8% and a negative net margin. The company updated its FY 2026 guidance to an EPS range of $10.70-$11.20. Analysts maintain a "Moderate Buy" rating with an average target price of $209.46, significantly above its current trading price.
Charles River Laboratories Announces Executive Appointments
Charles River Laboratories International, Inc. (NYSE: CRL) has announced two significant executive appointments to strengthen its leadership team. Glenn G. Coleman will join as Corporate Executive Vice President and Chief Financial Officer on April 6th, bringing over 30 years of financial and operational experience in the healthcare sector. Kerry Dailey will join as Corporate Senior Vice President and Chief Legal Officer on March 30th, overseeing legal, compliance, communications, government relations, security, and ESG initiatives.
Charles River Laboratories (CRL) Q4 revenue, adjusted earnings top expectations
Charles River Laboratories (CRL) reported stronger-than-expected revenue and adjusted earnings for the fourth quarter of fiscal 2025, despite a slight decline in revenue to $994.2 million. The company's adjusted earnings per share were $2.39, surpassing analysts' forecasts. For fiscal 2026, management anticipates revenue to be flat to up 1.5% and provided an adjusted EPS guidance range of $10.70 to $11.20.
Alcon (ALC) Veteran Joins Charles River as Chief Legal Officer
Kerry Dailey, an Alcon veteran with over ten years of experience, is moving to Charles River as Senior Vice President and Chief Legal Officer. This leadership change comes as Alcon, a leading vision care company, demonstrates strong financial health with robust margins, a solid balance sheet, and valuation metrics near historical lows. The company continues to show resilience and potential for growth in the healthcare sector despite leadership transitions.
Charles River Laboratories (NYSE:CRL) Beats Q4 CY2025 Sales Expectations
Charles River Laboratories (NYSE:CRL) reported Q4 CY2025 revenue of $994.2 million, surpassing analyst estimates, although sales were flat year-on-year. The company's non-GAAP EPS of $2.39 also beat consensus estimates, and its adjusted EPS guidance for FY2026 exceeded expectations. Despite challenges in operating margin, the company expressed optimism regarding stabilized biopharmaceutical demand and strategic initiatives for future growth.
Charles River: Q4 Earnings Snapshot
Charles River Laboratories International Inc. (CRL) reported a fourth-quarter loss of $276.6 million, or $5.62 per share. Adjusted earnings of $2.39 per share, and revenue of $994.2 million, both surpassed Wall Street expectations. For the full year, the company had a loss of $144.3 million on revenue of $4.02 billion and anticipates future full-year earnings between $10.70 and $11.20 per share.
Charles River: Q4 Earnings Snapshot
Charles River Laboratories International Inc. reported a Q4 loss of $276.6 million, or $5.62 per share, exceeding analyst expectations for adjusted earnings at $2.39 per share. The company's revenue for the quarter was $994.2 million, also surpassing Street forecasts. For the full year, Charles River recorded a loss of $144.3 million on revenues of $4.02 billion and anticipates full-year earnings between $10.70 and $11.20 per share.
Charles River: Q4 Earnings Snapshot
Charles River Laboratories International Inc. (CRL) reported a fourth-quarter loss of $276.6 million, or $5.62 per share, though adjusted earnings of $2.39 per share surpassed analyst expectations. The company also exceeded revenue forecasts, posting $994.2 million for the quarter. For the full year, Charles River recorded a loss of $144.3 million on revenues of $4.02 billion and anticipates full-year earnings between $10.70 and $11.20 per share.
Garmin Ltd. (GRMN) Tops Q4 EPS by 39c; offers guidance
Garmin Ltd. (GRMN) reported strong financial results for Q4, exceeding analyst estimates with an EPS of $2.79 on revenues of $2.12 billion. The company also provided optimistic guidance for FY2026, forecasting an EPS of $9.35 and revenue of $7.9 billion, both above consensus expectations. This positive outlook suggests continued growth and financial health for the company.
Charles River Laboratories 8-K Filing Analysis
Charles River Laboratories (CRL) has reported its financial results for Q4 and full-year 2025, showing a mixed performance with a slight revenue decrease and a GAAP loss per share, but non-GAAP earnings per share growth. The company is focusing on strategic acquisitions and efficiency improvements, and projects revenue to be at least flat to 1.5% and non-GAAP EPS to increase by 4% to 9% in 2026. Management expressed optimism about future growth driven by scientific innovation and strategic initiatives.
Charles River Labs beats Q4 expectations, provides cautious 2026 outlook
Charles River Laboratories International, Inc. (NYSE:CRL) exceeded analyst expectations for Q4 2025 with adjusted earnings of $2.39 per share and revenue of $994.2 million. Despite the beat, shares saw a slight decline in pre-market trading. The company provided a cautious outlook for fiscal year 2026, forecasting adjusted earnings of $10.70 to $11.20 per share and organic revenue ranging from a 1% decrease to flat, anticipating a return to growth in the second half of the year.
Charles River names Glenn Coleman as CFO, Kerry Dailey as CLO
Charles River Laboratories International Inc. (NYSE: CRL) has announced two significant executive appointments. Glenn G. Coleman is set to join as the new Chief Financial Officer, bringing over 30 years of financial management experience, while Kerry Dailey will take on the newly created role of Chief Legal Officer, leading the global legal and compliance functions. These appointments follow the interim CFO Michael G. Knell, and current General Counsel Matthew L. Daniel's planned departure.
Two new chiefs at Charles River Labs to steer finance and legal
Charles River Laboratories International, Inc. (NYSE: CRL) has announced two key executive appointments to strengthen its leadership team. Glenn G. Coleman will join as the new Chief Financial Officer, bringing over 30 years of financial and operational management experience in the healthcare sector. Kerry Dailey has been named to the newly-created position of Chief Legal Officer, with extensive expertise in advising multinational life science companies on legal and regulatory matters.
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance
Charles River Laboratories (NYSE: CRL) reported its Q4 and full-year 2025 financial results, showing a slight decrease in revenue but significant non-cash impairment charges impacting GAAP earnings. Despite the revenue dip, the company is cautiously optimistic for 2026, anticipating a return to organic revenue growth in the second half of the year due to stabilized biopharmaceutical demand and strategic initiatives, including a focus on efficiency and targeted acquisitions. The 2026 guidance projects non-GAAP earnings per share to increase by approximately 4% to 9%.
Charles River Laboratories Announces Executive Appointments
Charles River Laboratories International, Inc. (NYSE: CRL) has announced two significant executive appointments. Glenn G. Coleman will join as Corporate Executive Vice President and Chief Financial Officer, bringing over 30 years of financial and operational management experience in the healthcare sector. Kerry Dailey has been appointed to the new role of Corporate Senior Vice President and Chief Legal Officer, with 25 years of legal experience advising multinational life science companies.
Big impairments hit Charles River, but 2026 profit forecast rises
Charles River Laboratories (NYSE: CRL) reported its Q4 and full-year 2025 results, which included significant GAAP losses due to intangible asset and goodwill impairments totaling $376 million. Despite these write-downs, the company provided an optimistic outlook for 2026, forecasting an increase in non-GAAP earnings per share by approximately 4% to 9%. This improved forecast is driven by anticipated cost savings from restructuring initiatives and earnings accretion from recent acquisitions, with a projected return to organic revenue growth in the second half of 2026.
Charles River: Q4 Earnings Snapshot
Charles River Laboratories International Inc. (CRL) reported a Q4 loss of $276.6 million, or $5.62 per share, which adjusted to $2.39 per share, beating analyst expectations. The medical research equipment and services provider also exceeded revenue forecasts with $994.2 million for the quarter. For the full year, the company had a loss of $144.3 million on revenue of $4.02 billion and anticipates full-year earnings between $10.70 to $11.20 per share.
Charles River Laboratories Announces Executive Appointments
Charles River Laboratories International, Inc. (NYSE: CRL) announced two executive appointments: Glenn G. Coleman as the new Chief Financial Officer and Kerry Dailey as the inaugural Chief Legal Officer. These appointments are part of an effort to strengthen the leadership team and transform the company to meet evolving industry needs and enhance shareholder value. Coleman will join on April 6th, leading the global Finance organization, while Dailey will join on March 30th to oversee Legal, Compliance, Corporate Communications, Government Relations, Security, and Global ESG functions.
Pitney Bowes Shares Rise Following Full Year 2025 Results
Pitney Bowes Inc. (PBI) saw its shares increase by 1.89% after reporting its full year and Q4 2025 financial results. The company achieved a net income turnaround for the full year 2025 and reported a 40% increase in adjusted earnings per share for the fourth quarter. These improvements follow strategic moves like the wind-down of its Global Ecommerce segment and significant cost-reduction initiatives.
Why Labcorp (LH) Shares Are Trading Lower Today
Labcorp (LH) shares fell 2.7% after the company reported fourth-quarter revenue of $3.52 billion, which missed Wall Street's expectations of $3.57 billion, despite an earnings beat of $4.07 adjusted EPS. Although the company provided a solid full-year 2026 outlook, the revenue miss overshadowed the positive financial results, leading to the stock's decline. Labcorp's shares have shown relatively low volatility, making today's significant move noteworthy.
Charles River Laboratories Set to Announce Q4 Earnings
Charles River Laboratories (CRL) is preparing to release its Q4 2023 earnings report on February 18, with estimated EPS showing an 11.7% year-over-year decline and revenue a 1.3% dip, despite a strong historical record of beating estimates. The upcoming report and recent executive changes, including a new CEO, are key factors influencing market perception, alongside mixed revisions in analyst estimates. The company has also seen analysts raise price targets and is engaged in new collaborations while also facing a securities class action lawsuit.
Charles River Laboratories International, Inc. (NYSE:CRL) Given Consensus Recommendation of "Moderate Buy" by Analysts
Analysts have given Charles River Laboratories International, Inc. (NYSE:CRL) a "Moderate Buy" consensus rating based on reports from fifteen firms, with an average 12-month price target of $209.46. Institutional investors show strong confidence, owning approximately 98.91% of the company's stock, with several large firms recently increasing their positions. The company is a leading provider of research models and preclinical/clinical support services for the pharmaceutical, biotechnology, and medical device industries.
Charles River Laboratories (CRL) Q4 Earnings: What To Expect
Charles River Laboratories (CRL) is set to report its Q4 earnings on Wednesday. Analysts anticipate a 2.2% year-on-year revenue decline to $980.9 million and adjusted earnings of $2.35 per share. Despite solid past performance in beating revenue estimates, the stock has underperformed its peers recently, and ongoing economic uncertainties have impacted the broader drug development inputs & services segment.
Charles River Laboratories (CRL) Q4 Earnings: What To Expect
Charles River Laboratories (CRL) is set to report its Q4 earnings, with analysts expecting a 2.2% year-on-year revenue decline to $980.9 million and adjusted earnings of $2.35 per share. The company has generally beaten revenue estimates in the past, and analyst estimates have remained consistent. The broader drug development inputs & services segment has underperformed recently, with CRL's stock down 26.1% over the last month.
Why Charles River (CRL) Faces Sector Cancellation Jitters and Governance Scrutiny at the Same Time
Charles River Laboratories International (NYSE:CRL) is experiencing increased pressure due to rising project cancellations in the life sciences sector and a new investor rights law firm probe into potential fiduciary duty breaches. These issues, alongside an upcoming CEO transition, add complexity to the company's investment narrative ahead of its Q4 2025 earnings release. Despite these concerns, the company projects significant revenue and earnings growth by 2028, with some analysts also offering more pessimistic forecasts.
Lumentum stock drops after insider sales — what to know before the next session
Lumentum Holdings Inc. (LITE) shares dropped 3.6% to close at $562.74 after a volatile week, marked by insider sales from an executive and a director. The stock's recent decline is drawing attention, especially as it has been a high-beta bet on data-center optics. Investors will be closely watching for market reactions and any new filings when U.S. markets reopen on Tuesday after the Presidents Day holiday.
Charles River Laboratories International, Inc. $CRL Shares Bought by LSV Asset Management
LSV Asset Management significantly increased its stake in Charles River Laboratories International (NYSE:CRL) by 1,773.0% in the 3rd quarter, purchasing an additional 281,900 shares and now owning 297,800 shares worth $46.59 million. Other institutional investors also modified their holdings, and 98.91% of the stock is owned by institutional investors and hedge funds. The company currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $209.46.
Caprock Group LLC Buys Shares of 11,363 Charles River Laboratories International, Inc. $CRL
Caprock Group LLC has acquired a new position of 11,363 shares in Charles River Laboratories International (CRL), valued at approximately $1.856 million. The company shows high institutional ownership (98.91%), and analysts have given it a "Moderate Buy" rating with a consensus target price of $209.46. Several other institutional investors also increased their holdings in CRL recently.
12 Best Mid Cap AI Stocks to Buy According to Hedge Funds
This article highlights JFrog Ltd. (NASDAQ:FROG) as a key mid-cap AI stock favored by hedge funds, noting its strong growth profile and potential benefits from increased AI adoption. Analysts from Robert W. Baird and Bank of America Securities have reaffirmed Buy ratings, citing the company's role in managing binaries for AI-generated code and its accelerating cloud revenue. JFrog's tools for software supply chain management and risk mitigation position it as a direct beneficiary of the expanding AI market.
Mariner Partners with State Street to Use Its Charles River Wealth Management Platform
Mariner, a U.S. private equity-backed financial services firm, has partnered with State Street to implement its Charles River wealth management solution. This collaboration aims to optimize Mariner's operations, enhance advisor workflows, and support its long-term growth strategy, including a target of reaching 5,000 advisors. The centralized platform is designed to improve efficiency, ensure consistency, and allow advisors to focus more on client relationships.
Charles River Labs Quarterly Resilience Faces Declining Organic Revenue Test
Charles River Laboratories (NYSE:CRL) reported resilient quarterly results despite a 2.3% average annual decline in organic revenue over the past two years, leading to a recent stock pullback. Analysts anticipate modest revenue growth and lower return on invested capital, suggesting the company relies more on cost control and execution than volume growth. Investors should monitor the company's efforts to rebuild its project pipeline and improve its return on invested capital given the current market sentiment and share price volatility.
Halper Sadeh LLC Encourages Charles River Laboratories
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to shareholders. Long-term shareholders are encouraged to contact the firm to discuss potential corporate governance reforms, recovery of funds, or other benefits. The firm emphasizes that shareholder involvement can improve company policies and enhance shareholder value.
Halper Sadeh LLC Encourages Charles River Laboratories International, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders to contact them to discuss their legal rights and options, which may include seeking corporate governance reforms or the return of funds to the company. Shareholder participation is highlighted as important for improving company policies and enhancing shareholder value.
Stephens raises Westinghouse Air Brake stock price target to $290 on strong outlook
Stephens has increased its price target for Westinghouse Air Brake (NYSE: WAB) to $290 from $230, while reiterating an Overweight rating, following strong Q4 2025 earnings which surpassed expectations. The company also provided optimistic 2026 guidance, demonstrating robust order momentum and a strong free cash flow profile. This outlook positions WAB as a compelling long-term story in the rail technology sector, supported by both domestic and international demand.
Madison Asset Management LLC Purchases Shares of 12,366 Charles River Laboratories International, Inc. $CRL
Madison Asset Management LLC recently acquired 12,366 shares of Charles River Laboratories International, Inc. (NYSE:CRL) for approximately $1,935,000 during the third quarter. Other institutional investors also adjusted their holdings, with several firms initiating new positions or increasing existing ones. The stock is currently trading at $165.57, down 8.6%, with analysts offering a "Moderate Buy" rating and an average price target of $209.46.
